DDInter16 DDInter1607
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) downregulates {v} (Gene) NT5DC2
NT5DC2 {u} (Gene) is downregulated by {v} (Compound) Ritonavir
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methyldopa
Methyldopa {u} (Compound) causes {v} (Side Effect) Hepatocellular injury
Hepatocellular injury {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Sodium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Ritonavir (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) downregulates NT5DC2 (Gene) and NT5DC2 (Gene) is downregulated by Ritonavir (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa (Compound) causes Hepatocellular injury (Side Effect) and Hepatocellular injury (Side Effect) is caused by Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)